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Abstract
Background: Dilated cardiomyopathy (DCM) is a common form of cardiomyopathy causing systolic dysfunction
and heart failure. Rare variants in more than 30 genes, mostly encoding sarcomeric proteins and proteins of the
cytoskeleton, have been implicated in familial DCM to date. Yet, the majority of variants causing DCM remain to be
identified. The goal of the study is to identify novel mutations causing familial dilated cardiomyopathy.
Results: We identify FBXO32 (ATROGIN 1), a member of the F-Box protein family, as a novel DCM-causing locus. The
missense mutation affects a highly conserved amino acid and is predicted to severely impair binding to SCF
proteins. This is validated by co-immunoprecipitation experiments from cells expressing the mutant protein and
from human heart tissue from two of the affected patients. We also demonstrate that the hearts of the patients
with the FBXO32 mutation show accumulation of selected proteins regulating autophagy.
Conclusion: Our results indicate that abnormal SCF activity with subsequent impairment of the autophagic flux
due to a novel FBXO32 mutation is implicated in the pathogenesis of DCM.
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Background
Dilated cardiomyopathy (DCM) is a primary myocardial
disease characterized by dilatation and impaired systolic
function of one or both ventricles. DCM is often associ-
ated with atrial and /or ventricular arrhythmias and sud-
den death which can occur at any stage of the disease
[1]. DCM is a common cause of progressive heart failure
and the most frequent indication for cardiac transplant-
ation [2, 3]. The prevalence of DCM has been estimated
to be 1 in 2,500 individuals for idiopathic DCM although
recent sequencing data suggest that this number is
largely underestimated, as many patients are pre-
symptomatic [4]. Among patients with idiopathic DCM
20–50 % of the cases are familial (FDC) [5]. FDC is gen-
etically heterogeneous, with mutation in more than 30
genes reported to date [6].
The overlap between the genes mutated in hypertrophic
cardiomyopathy (HCM) and DCM makes it challenging
to establish clear genotype/phenotype correlation in DCM
[6, 7]. The vast majority of DCM-causing mutations are
rare or even private [8, 9]. However, the mutations re-
ported so far within the known genes are only responsible
for one-third of the genetic causes of DCM; so the causal
mutations in the majority of DCM patients remain un-
known [4].
The ubiquitin-proteasome system (UPS) is responsible
for the targeted degradation of proteins regulating piv-
otal signaling pathways in the heart [10]. Dysregulation
of the UPS can lead to major pathologies. For instance,
hyper-ubiquitination of proteins and increased expres-
sion of E1 (ubiquitin-activating) and E2 (ubiquitin-con-
jugating) enzymes have been reported in explants from
DCM patients [11]. The E3 ligase is a key enzyme in the
UPS as it recognizes specific protein substrates that
undergo ubiquitin conjugation [12].* Correspondence: cpoizat99@kfshrc.edu.sa1Cardiovascular Research Program, King Faisal Specialist Hospital & Research
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FBXO32(MAFbx1/ Atrogin1) is a cardiac and muscle
specific F-Box protein with E3 ligase activity that local-
izes at the sarcomere. FBXO32 is a component of the
SCF complex, which also includes SKP1, CUL1, and
ROC1. The protein serves as an adaptor that targets spe-
cific substrates for canonical- or non-canonical ubiquiti-
nation. FBXO32 was initially described as a key
mediator of skeletal muscle atrophy [13, 14]. Because of
its role in muscle atrophy, FBXO32 was expected to act
as a negative regulator of hypertrophy in heart muscle.
However, gain and loss of function studies in mice have
produced mixed phenotypes leaving open questions on
the functional role of FBXO32 in cardiac muscle [13,
15]. FBXO32 negatively regulates physiological cardiac
hypertrophy by enhancing the activity of Forkhead tran-
scription factors [16]. Under stress conditions, FBXO32
is also a negative regulator of pathological cardiac hyper-
trophy, which is associated with degradation of calcine-
urin A [13]. However, FBXO32 was also shown to be a
mediator of pathological cardiac remodeling via
stabilization of IκB-α [15]. In a rat model of chronic
heart failure after myocardial infarction, TNF-alpha in-
duces troponin I degradation through an FBXO32/
Murf1-dependent pathway [16]. Most recently, a role of
FBXO32 in myocardial aging was reported as FBXO32
deficiency led to cardiomyopathy over time due to im-
paired autophagy [17].
In the present study, we describe a family with FDC
that did not link to previously known DCM genes, and
identify FBXO32 as a new member of genes causing
FDC. We describe the first homozygous missense mu-
tation in FBXO32 that abrogates interaction with
members of the SCF complex, and is associated with
defects in proteins regulating the autophagy/lysosome
machinery.
Results
Identification of a family with DCM
The family was a consanguineous Saudi family con-
sisting of healthy parents who were first cousins, four
children with DCM, and six healthy siblings. FDC
was suspected based on the family history of DCM,
which was confirmed after cardiovascular screening of
at-risk family members. There was also a family his-
tory of heart transplantation as three of the affected
siblings (participants IV.5, IV.7, and IV.8) underwent
cardiac transplantation. Patient IV.4 was the first to
be diagnosed with DCM and was a candidate for
heart transplantation, which he rejected when his
condition deteriorated. The patient had a severe dila-
tation of all the cardiac chambers. Systolic function
was severely impaired and the ventricle was hypertra-
beculated. There was evidence of severe valve regurgi-
tation and elevated right ventricular (RV) systolic
pressure. Details of the clinical features of the family
are provided in Table S1 in Additional file 1.
The index (Patient IV.5) was diagnosed with DCM
during family screening. Echocardiography revealed a
moderately-to-severely dilated left ventricle (LV) with
hypertrabeculated cavities, and severely dilated left atria
(LA) (Figure S1 in Additional file 2), elevated filling
pressures and low cardiac output. LV function was se-
verely impaired with a pronounced global hypokinesis.
The RV was mildly dilated with severely reduced systolic
function. Like patient IV.4, the LA was severely dilated.
Three years post transplant the patient showed no sign
of recurrence of the disease.
Patient IV.7 was diagnosed with DCM during family
screening. The patient had multiple recurrent admis-
sions with decompensated heart failure. Echocardiog-
raphy showed a severe dilatation of the LV and LA
associated with a severely reduced ejection fraction (Fig-
ure S1 in Additional file 2). LV filling pressure raised
and there was evidence of moderate tricuspid regurgita-
tion after which the patient was transplanted.
Patient IV.8 was also diagnosed with DCM and under-
went cardiac transplantation after a deterioration of his
condition. Echocardiography prior to the cardiac trans-
plantation showed a severe dilatation of the LV and a se-
verely reduced LV systolic pressure and global
hypokinesis. LA was severely dilated while RA was mod-
erately to severely dilated.
Homozygosity mapping and linkage analysis identify a
novel DCM locus
Given the clinical symptoms and consanguinity in the
family, an autosomal recessive mode of inheritance was
proposed. After signing an informed consent, blood was
collected from the affected siblings, unaffected siblings,
and unaffected parents, and genotyping was performed
from extracted DNA. A single region of homozygosity
on chromosome 8 was shared between the affected sib-
lings (Figure S2 in Additional file 3). Linkage analysis re-
vealed a single peak on chromosome 8 (8q24.13) with a
maximum logarithm of odds (LOD) score of 3.4 (Fig. 1a)
corresponding to the same ROH (Run of homozygosity)
highlighted by autozygome analysis. The shared region
did not include any known DCM genes. Accordingly, we
performed whole exome sequencing to identify the novel
locus.
Exome sequencing identifies the pathogenic FBXO32
variant
Exome capture and sequencing was performed on the
index patient IV.5. A summary of the raw data charac-
teristics for the 100× coverage exome is described in
Table S2 (Additional file 4). The exome data were fil-
tered following the algorithm delineated in Fig. 1b. Only
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novel variants located within the ROH, homozygous,
coding/splicing were considered. Applying these criteria
resulted in the identification of a single novel missense
variant in FBXO32 gene NM_058229.3:c. 727G > C,
p.Gly243Arg (Fig. 1c). The variant was absent from 200
ethnically matched controls as well as 679 in-house
Saudi exomes and fully co-segregated with the DCM
phenotype within the family as confirmed by direct
Sanger sequencing (Fig. 2a). It is present at an extremely
low frequency at ExAC (http://exac.broadinstitute.org/
variant/14-92460188-C-T) of two heterozygotes from
among 120,748 alleles for a MAF of 0.00001656. The af-
fected amino acid residue Gly 243 was conserved across
multiple species down to zebrafish and across the known
F-Box protein sub-family [18] (Fig. 2b and c). The vari-
ant was predicted as pathogenic by PolyPhen-2 (prob-
ably damaging;1), MutationTaster (disease causing; 0.99),
SIFT (deleterious; 0.01) and PHRED (score of 26.4).
Based on these predictions and because FBXO32 has
been associated with cardiac diseases in loss and gain of
function studies in mice, we considered the FBXO32
variant further for functional analyses.
In silico modeling of the FBXO32 mutation predicts
alteration of the SCF complex
FBXO32 is part of the SCF (SKP-CUL1-F-Box) complex
of ubiquitin ligases, which targets specific substrates for
degradation. FBXO32 contains an F-Box domain re-
quired for proper interaction with SKP1, CUL1, and
ROC1 [14, 16, 19]. Because the identified variant is lo-
cated within the F-Box domain, we predicted that the
interaction of FBXO32 with SKP1 might be disrupted,
which may affect formation of the SCF complex and im-
pair its function as an E3-ligase. F-Box domains are
highly conserved in proteins [20]. Thus, we performed
in silico modeling to predict the effect of the variant on
the protein structure. Modeling of the F-Box domain of
FBXO32 was based on the canonical structure of FBW7
(PDB ID: 2OVR) [21] using I-TASSER [22]. The
FBXO32 Gly to Arg mutation (G243R) is predicted to lie
Fig. 1 Identification of a novel genetic mutation in dilated cardiomyopathy. a Linkage analysis reveals a single peak indicated by the red arrow.
b Stacked Venn diagram showing the filtering strategy to narrow down the novel locus
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on a helix at the interface between FBXO32 and SKP1
(Fig. 3a). Like the Pro residue in FBW7, the small G243
residue in FBXO32 packs tightly onto neighboring heli-
ces to maintain the correct architecture of the F-Box do-
main. The G to R substitution, a much larger residue, is
expected to distort the fold of the F-Box as the R clashes
with the surrounding helices (Fig. 3a). The outcome of
the p.G243R substitution is to disrupt the proper orien-
tation of F-Box residues interacting with SKP1, leading
to a loss of interaction required for forming the E3 ubi-
quitin ligase, thus abrogating the function of FBXO32.
The FBXO32 variant impairs the formation and function of
the SCF complex
CUL1 serves as a scaffolding protein that interacts with
SKP1 and ROC1, while FBXO32 binds SKP1 (Figure S3
in Additional file 5) [23]. To validate the prediction of
the structural modeling of the p.G243R substitution, we
Fig. 2 Location and conservation of the mutated amino acid. a DNA sequencing chromatograms showing the novel missense mutation in all
affected members with the site of mutation marked by an inverted red triangle. b Top: Schematic representation of FBXO32 with the different
domains of the protein and the G243R mutation in the F-Box domain. Bottom: multisequence alignment orthologs showing conservation of the
mutation (p. G243) across species. c Conservation across the sub-family of human F-Box proteins. The affected amino acid residue is boxed in red.
NLS = nuclear localization signals. PD = PDZ domain. LZ = leucine-zipper domain. LCD = leucine-charged residue-rich domain.
F-Box = F-Box domain
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next assessed interaction of wild-type (WT) FBXO32 or
mutant FBXO32-p.G243R with proteins of the SCF com-
plex. WT FBXO32 or mutant FBXO32 carrying a Flag
epitope were co-transfected with GFP-SKP1, myc-CUL1,
and HA-ROC1 in HEK293 cells, and FBXO32 was
immunoprecipitated using Flag resins followed by im-
munoblotting. CUL1 interacted efficiently with WT
FBXO32 but not with mutant FBXO32 (Fig. 3b). ROC1
and SKP1 also interacted with WT FBXO32 whereas
their binding with mutant FBXO32 was reduced (Fig. 3b).
Immunoprecipitation carried out first using CUL1
absorbed on c-Myc-beads confirmed that WT FBXO32
was part of the SCF complex, but not mutant FBXO32
which failed to efficiently precipitate with CUL1.
Fig. 3 FBXO32 mutation affects the molecular interaction with components of the SCF complex. a Homology model of FBXO32-SKP1 interaction
(right panel) based on the FBW7-SKP1 structure (left panel, PDB ID: 2OVR). FBXO32 is in ribbon representation (cyan) and SKP1 is in surface
representation (green). The Gly to Arg mutation, shown as white sticks leads to clashes (marked by red crosses) with neighboring helices in the
F-Box domain. b HEK293 cells co-transfected with the indicated plasmids. Equal amounts of protein lysates were co-immunoprecipitated with Flag
resines and analyzed by immunoblotting with the indicated antibodies. Blots are representative of three independent experiments. c Immunoblot
analysis after IP in patients IV.5 and IV.7 with FDC compared to Ctr (control) and IDC. IP was performed with control IgG antibody used a
negative control
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Consistent with proteins assembled in the SCF complex,
CUL1/SKP1 interaction was not affected by the FBXO32
mutation (Figure S3a in Additional file 5b and c).
The F-Box domain of FBXO32 is important for the
ubiquitination of specific substrates. Thus, we evaluated
the effect of the FBXO32 mutation on global ubiquitina-
tion of cellular proteins. Cells expressing mutant
FBXO32 displayed reduced ubiquitination of cellular
proteins compared to cells expressing WT FBXO32
(Figure S4a in Additional file 6). Furthermore, expression
of mutant FBXO32 in cardiomyocytes stabilized two
known substrates of FBXO32, CHMP2B, and Calcineurin
A (Figure S4b in Additional file 6).
Next we assessed FBXO32/SKP1/CUL1/ROC1 inter-
action in the heart of patients IV.5 and IV.7 with FDC
collected at the time of cardiac transplantation using im-
munoprecipitation. We also evaluated interaction in
control hearts and in the hearts of patients with idio-
pathic dilated cardiomyopathy (IDC). Strong binding of
FBXO32 with CUL1 was detected in control hearts.
Strikingly, FBXO32/CUL1 interaction was reduced in
hearts IV.5 and IV.7 but not in control hearts and in the
hearts of patients with IDC (Fig. 3c). Binding of FBXO32
with ROC1 and SKP1 was also reduced in hearts IV.5
and IV.7 but not in the heart of patients with IDC
(Fig. 3c). Together, these results indicate that the
FBXO32 mutation affects interaction of FBXO32 with
CUL1, ROC1, and SKP1, thus impairing proper forma-
tion of the SCF complex.
The autophagy/lysosome system is impaired in the hearts
of the patients with the FBXO32 mutation
FBXO32 regulates the stability of calcineurin A [13], an
important mediator of cardiac hypertrophy [24] (for Re-
view). IkB-α is also targeted for degradation by FBXO32
[15]. Thus we evaluated calcineurin A and IkB-α protein
expression in the control hearts, in hearts IV.5 and IV.7
from our recruited family, in a dilated heart of an unre-
lated family, and in IDC. Calcineurin A was upregulated
in hearts IV.5 and IV.7 and in the majority of the dis-
eased hearts (Figure S5 in Additional file 7), showing
that altered expression of calcineurin A is a common re-
sponse in dilated cardiomyopathy [25]. IkB-α protein
level was similar in the hearts IV.5 and IV.7 and in the
control hearts, suggesting that the FBXO32 mutation
does not regulate IkB-α expression.
FBXO32 has recently been shown to regulate the turn-
over of the charged multivesicular body protein 2B
(CHMP2B), an essential mediator for autophagosome-
lysosome fusion [17]. Based on this, we assessed
CHMP2B protein expression in our collection of hearts,
as well as the expression of the common autophagy
marker BECLIN-1. Immunoblot analysis showed that
CHMP2B and BECLIN-1 protein expression were in-
duced to variable degree in patient hearts IV.5 and IV.7
and in the other diseased hearts, indicating a similar re-
sponse in cardiomyopathy of familial and idiopathic ori-
gin (Fig. 4). Next, we assessed levels of the microtubule-
associated protein1 light chain 3 (LC3) and the conver-
sion of LC3-I to LC3-II which is an indicator of autoph-
agic activity [26]. Increased LC3-II was detected in
hearts IV.5 and IV.7 while it was almost undetectable in
the other familial heart and in the hearts of patients with
IDC, suggesting a block of autophagic flux in the heart
of patients carrying the FBXO32 mutation. Consistent
with this, expression of p62 (sequestosome 1, SQSTM1),
a selective autophagy substrate that accumulates when
autophagy is inhibited, increased more strongly in the
hearts of patients IV.5 and IV.7 compared to the other
diseased hearts [27]. Strikingly, expression level of the
lysosome-associated membrane protein-2 (LAMP2), a
marker of end-stage autophagy, strongly increased only
Fig. 4 The FBXO32 mutation impairs the expression of selected proteins of the autophagy/lysosomal system. Immunoblot blot analysis of the
indicated autophagy and lysosomal marker in FDC patients IV.5 and IV.7 carrying the FBXO32 variant, in a cardiomyopathic heart from another
family (FDC2), in idiopathic dilated hearts (IDC) and in control hearts (Ctr)
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in hearts IV.5 and IV.7 but not in the other cardiomyo-
pathic hearts. All together, these results suggest that al-
though autophagy is induced in the hearts of the
patients with the FBXO32 mutation, the execution of au-
tophagy is not complete.
Discussion
DCM is a disease of the myocardium causing left ven-
tricular enlargement and systolic dysfunction progres-
sing to heart failure. Rare variants in more than 30
genes have been reported to cause FDC most of which
encoding proteins of the sarcomere. However, the major-
ity of the DCM-causing mutations still remain to be
identified and the prevalence of DCM is believed to be
largely underestimated [4]. New variants emerging from
a large population-based study using exome data from
the NHLBI/GO Exome Sequencing Project indicate an
over-representation of cardiomyopathy-associated vari-
ants [28]. In this study, we identify FBXO32 as a new
locus causing DCM. Evidence that the FBXO32 muta-
tion is disease-causing is supported by the positional
mapping showing that the four affected patients in this
large family carry the homozygous mutation. Further-
more, the modeling and functional data show that the
mutation causes a defect in the SCF complex, which is
recapitulated in the two hearts of the patients with FDC.
Finally, our molecular analysis showed impaired expres-
sion of “late” autophagy markers in the two FDC hearts
but not in other cardiomyopathic hearts of familial and
idiopathic origin. These changes were also observed in a
mouse model of FBXO32 deficiency. Although we can-
not exclude the possibility that a non-genic mutation
may contribute to the pathogenesis of DCM in this family,
our exome sequencing data combined with the modeling
of the mutation and our functional analysis provide com-
pelling evidence that the FBXO32 variant is pathogenic.
DCM was initially suspected in the family from the
history of cardiac transplantation in three of the affected
patients. The fourth sibling was also recommended for
heart transplantation. FDC can be asymptomatic for
years or have incomplete penetrance, which can repre-
sent a challenge for accurate clinical diagnosis. Also,
variable penetrance and expression of the disease can
complicate DCM assessment. In our study, full clinical
evaluation including echocardiography was done by a
trained cardiologist who confirmed an early onset of the
disease in the four affected siblings.
Homozygosity for the FBXO32 mutation segregated
with the affected status of the siblings in the family. Be-
cause most of the DCM-causing mutations are rare, we
screened 679 in-house Saudi exomes and performed
Sanger sequencing from 200 ethnically-matched con-
trols. The variant was predicted to have a damaging ef-
fect on FBXO32 protein structure according to four
different web-based programs and was found at an ex-
tremely low frequency (MAF of 0.00001656). These fea-
tures together with the high conservation of the affected
amino acid across species and within the sub-family of
F-BOX proteins are consistent with the variant being
disease-causing.
FBXO32 is a component of the SCF family of ubiquitin
ligases. The F-Box domain of FBXO32 functions as an
adaptor that binds SKP1 and thereby CUL1 and ROC1
[29]. Because the G243R variant is located in the F-Box
domain, we hypothesized that the mutation may impair
proper assembly of the SCF and affect its function. Mod-
eling of the variant from the crystal structure of FBW7
predicted loss of interaction between FBXO32 and
SKP1. Our co-precipitation experiments showed that an
intact F-Box is critical for FBXO32 to bind other mem-
bers of the SCF as interaction with CUL1 was strongly
impaired when G243 was mutated to R. Furthermore,
expression of mutant FBXO32 in cells resulted in a gen-
eral ubiquitination defect. Most importantly, interaction
of FBXO32 with SKP1 was disrupted in the two hearts
of the patients carrying the FBXO32 mutation while
interaction was intact in control and IDC hearts. These
results indicate that the mutation in the F-Box domain
of FBXO32 disrupts binding of several key proteins of
the SCF complex causing dysregulated degradation of
specific cellular proteins.
Gain and loss of function studies in transgenic and
knockout mice revealed a role of FBXO32 in maladap-
tive cardiac remodeling through regulation of calcine-
urin A and IkB-α [15, 16]. Thus, we thought to evaluate
calcineurin A and IkB-α expression in the heart of the
patients with the FBXO32 mutation. In agreement with
previous reports [30], calcineurin A was induced in hu-
man heart failure. However, calcineurin A was increased
in all cardiomyopathic hearts of familial or idiopathic
etiology, suggesting that stabilization of calcineurin A is
a common feature of end-stage heart failure rather than
a unique characteristic of the FBXO32 mutation. IkB-α
protein expression was similar in control hearts and in
the hearts of the two patients carrying the FBXO32 mu-
tation, also ruling out that stabilization of IkB-α is a
major contributor to the cardiomyopathy in the affected
patients.
The recent finding that FBXO32 deficiency causes an
aging-related cardiomyopathy in mice due to impaired
autophagy provided the first direct link between
FBXO32 and the autophagy system [17]. This study
prompted us to evaluate the role of this conserved cata-
bolic pathway in the pathogenesis of the FDC. Our bio-
chemical analysis showed increased expression of
selected proteins implicated in the “late” stage of the au-
tophagy system in the two hearts with the FBXO32 mu-
tation. Indeed, we detected a remarkable accumulation
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of LAMP2 in the hearts of the patients carrying the
FBXO32 variant but not in the heart of another patient
with FDC or in other DCM hearts. Since there is ample
documentation between dysregulation of the autophagic
flux and the development of heart failure and of other
cardiovascular diseases [31–33], our data suggest a late-
stage inhibition in autophagosome processing in the af-
fected patients. Thus, the defect in the last step of the
autophagic pathway observed in the human hearts with
the FBXO32 mutation, which is also recapitulated in
aging FBXO32-deficient mice, is likely to contribute to
the cardiomyopathy.
Conclusion
Overall, our study identifies FBXO32 as a new locus for
recessive DCM. Our biochemical analysis revealed that
the mutation alters the formation and function of the
SCF complex. Assessment of FBXO32 molecular targets
in cardiac tissue of the affected individual suggests that
the FBXO32 mutation causes cardiomyopathy through
impaired expression of selective proteins of the autoph-
agy system (Fig. 5). This study may open new diagnostic
testing for patients with FDC with potential new win-
dows for disease treatment.
Methods
Patient recruitment
The family is from Saudi Arabia. Patients were evaluated
by a board-certified cardiologist. All participants pro-
vided written informed consent under protocols ap-
proved by the Institutional Review Board at King Faisal
Specialist Hospital & Research Centre (RAC#2100 024
and #2010 020). Further details can be provided to re-
searchers upon request. The study was carried out in ac-
cordance with the principles of the Declaration of
Helsinki.
Human hearts
Control donor hearts were from patients with no sign of
cardiac disease whose hearts could not be transplanted
due to ABO mismatch. The hearts of one patient from
another family with DCM was collected as an additional
control. Three patients with idiopathic dilated cardiomy-
opathy (IDC) were collected at the time of cardiac trans-
plantation. We were also able to collect the hearts of
two of the affected siblings in our family, patients IV.5
and IV.7. Written informed consent was obtained for all
the patients that underwent heart transplantation after
IRB approval (RAC# 2100 024). The hearts were care-
fully dissected in the same anatomical regions, and tis-
sues from the left ventricle were used for biochemical
and histological analyses.
Echocardiography
Echocardiography was performed for patients IV.5 and
IV.7 prior to the cardiac transplantation. The other af-
fected siblings were also evaluated by echocardiography
to assess the presence or absence of DCM.
DNA extraction, genotyping, linkage analysis, and
homozygosity mapping
Genomic DNA was extracted from venous blood col-
lected from all the family members. Genome-wide geno-
typing was performed using the Axiom SNP ChIP
Fig. 5 Hypothetical model of impaired autophagy flux mediated by the mutated FBXO32. a SCF complex containing FBXO32 induces the
ubiquitination and subsequent degradation of target proteins. b Mutation in FBXO32 results in an inactive SCF complex, which stabilizes selective
proteins regulating autophagy resulting in heart failure
Al-Yacoub et al. Genome Biology  (2016) 17:2 Page 8 of 11
platform (Affymetrix, Santa Clara, CA, USA) followed
by AutoSNPa software used to identify homozygous in-
tervals of more than 1 Mb in length (http://dna.leeds.ac.
uk/autosnpa/). Linkage analysis was performed using
Easy Linkage software and multipoint LOD scores were
calculated assuming an autosomal recessive mode of
transmission.
Exome sequencing
Whole-exome sequencing was performed using TruSeq
Exome Enrichment kit (Illumina, San Diego, CA, USA).
Exome capture was performed according to the Illumina
protocols using TruSeq Exome Enrichment kit (Illumina).
Briefly, samples were prepared as an Illumina sequencing
library, and in the second step, the sequencing libraries
were enriched for the desired target using the Illumina
Exome Enrichment protocol. The captured libraries were
sequenced using the Illumina HiSeq 2000 Sequencer.
The reads were mapped by BWA (http://bio-bwa.source
forge.net/) against UCSC hg19 (http://genome.ucsc.edu/).
The SNPs and Indels were detected by SAMTOOLS
(http://samtools.sourceforge.net/). The variant Databases
dbSNP and 1000G were used to determine the variant fre-
quency. The full detail of the data coverage and sequen-
cing depth can be found in Additional file 4 Table S2.
Variants from WES were filtered such that only novel,
coding/splicing, homozygous variants that are within the
autozygome shared between the affected in the family
and not present in the 679 in-house Saudi exomes as de-
scribed before [34]. Variants remaining after this filtering
process were prioritized based on being predicted as
disease causing by pathogenicity predictor tools (Mutation
taster (http://www.mutationtaster.org/); Polyphen2 (http://
genetics.bwh.harvard.edu/pph2/)), SIFT (http://sift.jcvi.org/),
and CADD score (http://cadd.gs.washington.edu/).
PCR
Variants of interest were validated by PCR amplification
of the variant-containing exon from the original patient
sample, followed by Sanger sequencing. Genes located
within the ROH (Runs of homozygosity) which were not
fully covered by the exome sequencing, were also dir-
ectly sequenced using Sanger sequencing.
Site-directed mutagenesis of FBXO32
The FBXO32 mutation was generated by site-directed
mutagenesis using QuikChange II Site-Directed Muta-
genesis Kit (Agilent Technologies). Overlapping PCR
was used to introduce a site-specific point mutation.
The used primers were: 5′- GCAGAGGCTGAGCGAC
(C)GGCGGGACCTGGTCAG -3′ and 5′- CTGACCA
GGTCCCGCCGGTCGCTCAGCCTCTGC -3′. The base
change (G to C) in the relevant nucleotide is shown in
parentheses. Each PCR reaction (50 μL) contained 50 ng
FBXO32-MYC-DDK plasimd, 5 μL 10× reaction buffer,
1.5 μL dNTPs, 125 ng forward primer and 125 ng reverse
primer, and 2.5 U Pfu ultra High-Fidelity DNA polymer-
ase. The thermal cycle program was 95 °C/5 min, followed
by 18 cycles of (95 °C/50 s, 55 °C/50 s, 68 °C/7 min)
and a final extension step of 68 °C for 7 min. After-
wards the PCR product was treated with DpnI for
1 h at 37 °C and transformed into XL1-Blue compe-
tent cells provided by the kit. The mutagensis product
was verified by sequencing.
Cell culture
HEK293 cells were maintained in DMEM (10%FCS, 1 %
Pen/Strep). Primary neonatal rat cardiomyocytes were
isolated using the Worthington Neonatal Cardiomyocyte
Isolation System (Worthington Biochemical Corp, USA)
following the manufacturer’s instruction.
Transfection of cells
Twenty-four hours before transfection, cells were seeded
to be 60–70 % confluent at the time of transfection. The
next day the transfection was performed using Lipofec-
tamine® 2000 (Invitrogen™, USA) according to the manu-
facturer’s protocol. HEK 293 Cells were co-transfected
with WT FBXO32 or mutant FBXO32 carrying a Flag
epitope, Myc-tagged CUL1 and GFP-SKP1. Forty-eight
hours post transfection, total cell lysates were prepared
and analyzed by immunoblotting or subjected to immu-
noprecipitation. Isolated primary neonatal rat cardio-
myocytes were transfected 12 h after isolation with the
indicated plasmids using Lipofectamine® 2000 (Invitrogen™,
USA) according to the manufacturer’s protocol. 16 hours
post transfection, media was changed. Forty-eight hours
post transfection, cell lysates were prepared and analyzed
by immunoblotting using the indicated antibodies.
Plasmids and antibodies
Eukaryotic expression vectors for FBXO32 carrying a
Flag epitope (Flag-FBXO32), Myc-CUL1, and GFP-SKP1
were purchased from Origene. Antibodies against
FBXO32, cMyc, CUL1, SKP1, HA (Hemagglutinin),
GAPDH, and ROC-1 were purchased from Santa Cruz.
BECLIN-1, CHMP2B, LAMP2, FBXO32 (mAB), LC3a/B,
and p62 were purchased from Abcam, calcineurin A and
IkB-α were from Cell Signaling, and IkB-α was from
Abcam.
Protein extraction and immunoblot analysis
Protein extracts from human heart tissue were prepared
by grinding the tissue in liquid nitrogen followed by
homogenization using sonication in a lysis buffer sup-
plemented with protease inhibitor cocktail. After
centrifugation at 12,000 rpm at 4 °C for 10 min, super-
natants were recovered and used for immunoblot or
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immunoprecipitation analyses. Thirty micrograms of
protein from tissue or whole cell extracts were separated
on 4–12 % NuPAGE® Novex® Bis-Tris Gels (Invitrogen,
USA) and transferred onto nitrocellulose membrane. After
blocking of the membranes, the indicated primary anti-
bodies were incubated overnight at 4 °C. Secondary re-
actions were performed for 1 h and after washing,
chemiluminescence was performed and the signals were
visualized using LAS 4000 analyzer (GE) and analyzed
by ImageQuant software. For immunoprecipitation,
400–700 μg of total cell lysates were incubated with
Flag- or Myc-resins (Sigma) coupled with primary anti-
body or control IgG in a buffer supplemented with pro-
tease inhibitors for 2 h at 4 °C. After centrifugation, the
beads were washed and after elution, proteins were re-
solved by SDS-PAGE and immunoblotting was performed
as described before.
Availability of supporting data
The exome file is kept a searchable and secured access
database that can be accessed at http://shgp.kfshrc.edu.
sa/bioinf/db/variants/dg. The username and password
can be given upon request.
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Additional files
Additional file 1: Table S1. Clinical characteristics of the studied family.
(DOCX 82 kb)
Additional file 2: Figure S1. Echocardiographic images of patients
from the studied family. Echocardiography performed on two of the
affected siblings index patients IV.5 (a) and IV.7 (b) prior to heart
transplantation. M-mode echo and parasternal long-axis view showing
dilatation of the left ventricle and of the left atria with severe hypokinesia.
(TIF 5479 kb)
Additional file 3: Figure S2. Autozygome analysis in the studied
family. Autozygosity mapping was performed using AgileMultideogram.
The result is showing the single shared ROH (runs of homozygosity)
on chromosome 8 between the four affected members (dark blue).
(TIF 4051 kb)
Additional file 4: Table S2. Coverage and sequencing depth of the
exome data. (DOCX 17 kb)
Additional file 5: Figure S3. Mutation in FBXO32 abrogates binding to
SKP1 within the SCF complex. a Schematic representation of the SCF
complex. The FBXO32 mutation represented as a black triangle is
within the F-Box domain which normally mediates binding to SKP1. b
Immunoprecipitation showing reduced interaction of mutant FBXO32
with CUL1 after co-transfection of HEK293 cells with WT-FBXO32 or
mutant-FBXO32 and CUL1, ROC1, and SKP1. c Quantitative analysis of
(b) from three independent experiments. (TIF 2185 kb)
Additional file 6: Figure S4. Ubiquitination defect in cells expressing
mutant FBXO32. a Co-immunopricipitation analysis. HEK293 cells were
transfected with the indicated plasmids and immunoblot analysis was
performed from total cell lysates using a specific anti-ubiquitin antibody.
FBXO32 expression is shown as well as GAPDH. The blot is representative
of three independent experiments. b Immunoblot analysis of the
ubiquitination in cardiomyocytes. Cells were transfected with the
Flag-FBXO32-WT or Flag-FBXO32-Mutant and whole cell extracts were
analyzed by immunoblotting using the indicated antibodies. (TIF 1928 kb)
Additional file 7: Figure S5. Expression of the FBXO32 substrates
calcineurin A and IkB-α in FDC and IDC. Immunoblot analysis showing
calcineurin A and IkB-α protein expression in control hearts, in the heart
of patients IV.5 and IV.7 carrying the FBXO32 variant, in a cardiomyopathic
heart from another family (FDC2) and in idiopathic dilated hearts (IDC).
FBXO32 and GAPDH are also shown. (TIF 3699 kb)
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ROH: Runs of homozygosity; RV: Right ventricle.
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